Dr. Baris Ata Borsa graduated from Istanbul University Cerrahpasa Medical Faculty in 2004 and obtained Medical Microbiology Specialist degree in 2009 after 4 years of residency period at Sisli Etfal Training and Research Hospital, Istanbul.
From 2009 to 2013, he worked in different hospitals as specialist. In 2013, his academic career started as Assistant Professor at Altinbas University School of Medicine, Department of Medical Microbiology where he worked for 4 years. In this faculty, he was also responsible for many administrative assignments such as being Vice Dean of Medical Faculty, member of University Board of Education, and Head of Medical Microbiology Department.
During the same years, he was also working as a specialist at Özel Doga Hospital and doing PhD at Istanbul University Cerrahpasa Medical Faculty, Department of Medical Microbiology.
In 2017, he started working at Yeditepe University Medical Faculty, Department of Medical Microbiology as Assistant Professor and Yeditepe University Hospitals as specialist.
He obtained Associate Professor degree from Turkish Presidency of Inter-University Council in 2018. Same year, he joined Frank Hernendez's group as postdoctoral researcher at Linköping University for a new journey aiming to develop new targeted antibiotics which were becoming crucial because of globally increasing antimicrobial resistance.
His main research field is medical bacteriology, particularly antimicrobial resistance, even though he worked in all other sub-disciplines of the field (virology, mycology, parasitology, immunology, molecular microbiology) for many years. In his current project, he developed a first-in-kind targeted oligonucleotide antibiotic against a major human pathogen, Staphylococcus aureus, using its nuclease enzyme activity as biomarker.
He is also co-inventor in the patent application of this new therapeutic approach.
